Malinova, Vesna

[["dc.bibliographiccitation.journal","Translational Stroke Research"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Schroeder, Henning"],["dc.contributor.author","Fischer, André"],["dc.contributor.author","Sperling, Swetlana"],["dc.contributor.author","Ninkovic, Milena"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2022-02-01T10:31:59Z"],["dc.date.available","2022-02-01T10:31:59Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Cerebral vasospasm is a highly investigated phenomenon in neurovascular research. Experimental vasospasm models are irreplaceable for the evaluation of new antivasospastic drugs. In this study, we assessed the reliability of in vivo vasospasm induction by ultrasound application in the chicken chorioallantoic membrane (CAM) model. After incubation of fertilized chicken eggs for four days, a fenestration was performed to enable examination of the CAM vessels. On the thirteenth day, continuous-wave ultrasound (3 MHz, 1 W/cm 2 ) was applied on the CAM vessels for 60 s. The ultrasound effect on the vessels was recorded by life imaging (5-MP HD-microscope camera, Leica®). The induced vessel diameter changes were evaluated in a defined time interval of 20 min using a Fiji macro. The vessel diameter before and after sonication was measured and the relative diameter reduction was determined. A first reduction of vessel diameter was observed after three minutes with an average vessel-diameter decrease to 77%. The maximum reduction in vessel diameter was reached eight minutes after sonication with an average vessel diameter decrease to 57% (mean relative diameter reduction of 43%, range 44–61%), ANOVA, p  = 0.0002. The vasospasm persisted for all 20 recorded minutes post induction. Vasospasm can be reliably induced by short application of 3 MHz-ultrasound to the CAM vessels. This might be a suitable in vivo model for the evaluation of drug effects on vasospasm in an experimental setting as intermediary in the transition process from in vitro to in vivo assessment using animal models."],["dc.description.abstract","Abstract Cerebral vasospasm is a highly investigated phenomenon in neurovascular research. Experimental vasospasm models are irreplaceable for the evaluation of new antivasospastic drugs. In this study, we assessed the reliability of in vivo vasospasm induction by ultrasound application in the chicken chorioallantoic membrane (CAM) model. After incubation of fertilized chicken eggs for four days, a fenestration was performed to enable examination of the CAM vessels. On the thirteenth day, continuous-wave ultrasound (3 MHz, 1 W/cm 2 ) was applied on the CAM vessels for 60 s. The ultrasound effect on the vessels was recorded by life imaging (5-MP HD-microscope camera, Leica®). The induced vessel diameter changes were evaluated in a defined time interval of 20 min using a Fiji macro. The vessel diameter before and after sonication was measured and the relative diameter reduction was determined. A first reduction of vessel diameter was observed after three minutes with an average vessel-diameter decrease to 77%. The maximum reduction in vessel diameter was reached eight minutes after sonication with an average vessel diameter decrease to 57% (mean relative diameter reduction of 43%, range 44–61%), ANOVA, p  = 0.0002. The vasospasm persisted for all 20 recorded minutes post induction. Vasospasm can be reliably induced by short application of 3 MHz-ultrasound to the CAM vessels. This might be a suitable in vivo model for the evaluation of drug effects on vasospasm in an experimental setting as intermediary in the transition process from in vitro to in vivo assessment using animal models."],["dc.identifier.doi","10.1007/s12975-021-00960-y"],["dc.identifier.pii","960"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98997"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.relation.eissn","1868-601X"],["dc.relation.issn","1868-4483"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","In Vivo Vasospasm Induction by Ultrasound Application in the Chicken Chorioallantoic Membrane Model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hazaymeh, Mohammad"],["dc.contributor.author","Löber-Handwerker, Ronja"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Abboud, Tammam"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2022-12-01T08:30:57Z"],["dc.date.available","2022-12-01T08:30:57Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Approximately 25% of glioblastomas show at diagnosis a corpus callosum infiltration, which is associated with poor prognosis. The extent of corpus callosum involvement, however, ranges from partial unilateral to complete bilateral infiltration. The role of surgery in glioblastoma with corpus callosum involvement is controversial. In this study, we aimed to examine prognostic differences between glioblastoma with unilateral and glioblastoma with bilateral corpus callosum infiltration, and to evaluate possible treatment strategy implications. Patients with newly diagnosed glioblastoma from 2010 to 2019 were included. Corpus callosum infiltration was assessed in contrast-enhanced T1-weighted preoperative magnetic resonance imaging. Extent of resection, adjuvant treatments and overall survival were evaluated. Corpus callosum involvement was found in 96 (26.4%) out of 363 patients with newly diagnosed glioblastoma. Bilateral corpus callosum infiltration was found in 27 out of 96 patients (28%), and 69 patients had unilateral corpus callosum infiltration. Glioblastoma with corpus callosum affection had significantly lower median overall survival compared to glioblastoma without corpus callosum involvement (9 vs. 11 months,\n p\n  = 0.02). A subgroup analysis of glioblastoma with unilateral corpus callosum infiltration revealed a significant difference in median overall survival dependent on extent of resection (6.5 without gross total resection vs. 11 months with gross total resection, Log-rank test\n p\n  = 0.02). Our data confirms a shorter overall survival in glioblastoma subpopulation with corpus callosum involvement, especially for glioblastoma with bilateral corpus callosum infiltration. However, patients with partial corpus callosum infiltration undergoing gross total resection exhibited a significant survival benefit compared to their counterparts without gross total resection. Whenever reasonably achievable gross total resection should be considered as an integral part of the treatment strategy in glioblastoma with partial corpus callosum infiltration."],["dc.identifier.doi","10.1038/s41598-022-23794-6"],["dc.identifier.pii","23794"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118028"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2045-2322"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic differences and implications on treatment strategies between butterfly glioblastoma and glioblastoma with unilateral corpus callosum infiltration"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neurosurgical Review"],["dc.contributor.author","Löber-Handwerker, Ronja"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Bock, Christoph"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2022-04-01T10:01:06Z"],["dc.date.available","2022-04-01T10:01:06Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Patients with inoperable glioblastoma (GBM) usually experience worse prognosis compared to those in whom gross total resection (GTR) is achievable. Considering the treatment duration and its side effects identification of patients with survival benefit from treatment is essential to guarantee the best achievable quality of life. The aim of this study was to evaluate the survival benefit from radio-chemotherapy and to identify clinical, molecular, and imaging parameters associated with better outcome in patients with biopsied GBMs. Consecutive patients with inoperable GBM who underwent tumor biopsy at our department from 2005 to 2019 were retrospectively analyzed. All patients had histologically confirmed GBM and were followed up until death. The overall survival (OS) was calculated from date of diagnosis to date of death. Clinical, radiological, and molecular predictors of OS were evaluated. A total of 95 patients with biopsied primary GBM were enrolled in the study. The mean age was 64.3 ± 13.2 years; 56.8% (54/95) were male, and 43.2% (41/95) female. Median OS in the entire cohort was 5.5 months. After stratification for adjuvant treatment, a higher median OS was found in the group with adjuvant treatment (7 months, range 2–88) compared to the group without treatment (1 month, range 1–5) log-rank test, p  < 0.0001. Patients with inoperable GBM undergoing biopsy indeed experience a very limited OS. Adjuvant treatment is associated with significantly longer OS compared to patients not receiving treatment and should be considered, especially in younger patients with good clinical condition at presentation."],["dc.identifier.doi","10.1007/s10143-022-01754-y"],["dc.identifier.pii","1754"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105601"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1437-2320"],["dc.relation.issn","0344-5607"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Defining the impact of adjuvant treatment on the prognosis of patients with inoperable glioblastoma undergoing biopsy only: does the survival benefit outweigh the treatment effort?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","S1773224721005141"],["dc.bibliographiccitation.firstpage","102834"],["dc.bibliographiccitation.journal","Journal of Drug Delivery Science and Technology"],["dc.bibliographiccitation.volume","66"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Sperling, Swetlana"],["dc.contributor.author","Ninkovic, Milena"],["dc.contributor.author","Gasimov, Turab"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Streit, Frank"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2021-12-01T09:23:36Z"],["dc.date.available","2021-12-01T09:23:36Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.jddst.2021.102834"],["dc.identifier.pii","S1773224721005141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94703"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.issn","1773-2247"],["dc.title","Ultrasound-induced release of nimodipine from drug-loaded block copolymers: In vitro analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Translational Stroke Research"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Sperling, Swetlana"],["dc.contributor.author","Ninkovic, Milena"],["dc.contributor.author","Schroeder, Henning"],["dc.contributor.author","Fischer, André"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Streit, Frank"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2022-02-01T10:31:59Z"],["dc.date.available","2022-02-01T10:31:59Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Nimodipine prevents cerebral vasospasm and improves functional outcome after aneurysmal subarachnoid hemorrhage (aSAH). The beneficial effect is limited by low oral bioavailability of nimodipine, which resulted in an increasing use of nanocarriers with sustained intrathecal drug release in order to overcome this limitation. However, this approach facilitates only a continuous and not an on-demand nimodipine release during the peak time of vasospasm development. In this study, we aimed to assess the concept of controlled drug release from nimodipine-loaded copolymers by ultrasound application in the chicken chorioallantoic membrane (CAM) model. Nimodipine-loaded copolymers were produced with the direct dissolution method. Vasospasm of the CAM vessels was induced by means of ultrasound (Physiomed, continuous wave, 3 MHz, 1.0 W/cm 2 ). The ultrasound-mediated nimodipine release (Physiomed, continuous wave, 1 MHz, 1.7 W/cm 2 ) and its effect on the CAM vessels were evaluated. Measurements of vessel diameter before and after ultrasound-induced nimodipine release were performed using ImageJ. The CAM model could be successfully carried out in all 25 eggs. After vasospasm induction and before drug release, the mean vessel diameter was at 57% (range 44–61%) compared to the baseline diameter (set at 100%). After ultrasound-induced drug release, the mean vessel diameter of spastic vessels increased again to 89% (range 83–91%) of their baseline diameter, which was significant ( p  = 0.0002). We were able to provide a proof of concept for in vivo vasospasm induction by ultrasound application in the CAM model and subsequent resolution by ultrasound-mediated nimodipine release from nanocarriers. This concept merits further evaluation in a rat SAH model. Graphical abstract"],["dc.description.abstract","Abstract Nimodipine prevents cerebral vasospasm and improves functional outcome after aneurysmal subarachnoid hemorrhage (aSAH). The beneficial effect is limited by low oral bioavailability of nimodipine, which resulted in an increasing use of nanocarriers with sustained intrathecal drug release in order to overcome this limitation. However, this approach facilitates only a continuous and not an on-demand nimodipine release during the peak time of vasospasm development. In this study, we aimed to assess the concept of controlled drug release from nimodipine-loaded copolymers by ultrasound application in the chicken chorioallantoic membrane (CAM) model. Nimodipine-loaded copolymers were produced with the direct dissolution method. Vasospasm of the CAM vessels was induced by means of ultrasound (Physiomed, continuous wave, 3 MHz, 1.0 W/cm 2 ). The ultrasound-mediated nimodipine release (Physiomed, continuous wave, 1 MHz, 1.7 W/cm 2 ) and its effect on the CAM vessels were evaluated. Measurements of vessel diameter before and after ultrasound-induced nimodipine release were performed using ImageJ. The CAM model could be successfully carried out in all 25 eggs. After vasospasm induction and before drug release, the mean vessel diameter was at 57% (range 44–61%) compared to the baseline diameter (set at 100%). After ultrasound-induced drug release, the mean vessel diameter of spastic vessels increased again to 89% (range 83–91%) of their baseline diameter, which was significant ( p  = 0.0002). We were able to provide a proof of concept for in vivo vasospasm induction by ultrasound application in the CAM model and subsequent resolution by ultrasound-mediated nimodipine release from nanocarriers. This concept merits further evaluation in a rat SAH model. Graphical abstract"],["dc.identifier.doi","10.1007/s12975-021-00979-1"],["dc.identifier.pii","979"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98998"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.relation.eissn","1868-601X"],["dc.relation.issn","1868-4483"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Ultrasound-Induced Release of Nimodipine from Drug-Loaded Block Copolymer Micelles: In Vivo Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Clinical Neuroradiology"],["dc.contributor.author","Döring, Katja"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Stamm, Georg"],["dc.contributor.author","Karsch, Susanne"],["dc.contributor.author","Psychogios, Marios-Nikos"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Malinova, Vesna"],["dc.date.accessioned","2021-10-01T09:58:49Z"],["dc.date.available","2021-10-01T09:58:49Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00062-021-01087-1"],["dc.identifier.pii","1087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90151"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","1869-1447"],["dc.relation.issn","1869-1439"],["dc.title","Radiation Exposure in the Acute Phase after Aneurysmal Subarachnoid Hemorrhage in the Era of CT Perfusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]